Physician profile
Hamid Mortazavi
NPI 1134145758
$10,140.26
in general payments reported to CMS, 2019-2025
53 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8.53 · 2022: $1,344 · 2023: $4,028 · 2024: $3,816 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,788.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.91 | 2022-2025 | |
| Pfizer INC. | $747.20 | 2023-2025 | |
| Biogen, INC. | $642.17 | 2022-2025 | Vumerity, Tysabri, Skyclarys |
| Mdd US Operations, LLC | $548.26 | 2022-2025 | Gocovri, Gocovri |
| Lundbeck LLC | $501.74 | 2023-2025 | Vyepti, Rexulti |
| Celgene Corporation | $477.94 | 2022-2024 | Zeposia |
| Neurelis, INC. | $469.10 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $455.93 | 2022-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $393.68 | 2022-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $382.29 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Otsuka America Pharmaceutical, INC. | $298.27 | 2023-2024 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $297.75 | 2022-2025 | |
| Ucb, INC. | $273.56 | 2022-2024 | Briviact, Fintepla, Rystiggo |
| Kyowa Kirin, INC. | $260.63 | 2023-2024 | Nourianz |
| Alexion Pharmaceuticals, INC. | $236.49 | 2022-2024 | Ultomiris, Soliris |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Mortazavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.